Enalare Therapeutics Inc. — Form D
Enalare Therapeutics Inc. of PRINCETON, NJ, a company, filed a Form D exempt-offering notice with the SEC on 2022-08-15. The offering totals $55.0M, of which $12.5M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2022-08-15
- Form: D
- Accession: 0001835701-22-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $55.0M
- Amount sold: $12.5M
- Remaining: $42.5M
- Investors: 1
- Date of first sale: 2022-08-08
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-456016
Issuer
- Name: Enalare Therapeutics Inc.
- CIK: 0001835701
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 161 HODGE ROAD, PRINCETON, NJ, 08540
- Phone: 609-325-7701
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Mark Coleman | Director | ROCKVILLE, MD |
| Herman Cukier | Director | Princeton, NJ |
| Joseph Pergolizzi | Director | Summit, NJ |
| Joseph Petko | Director | Princeton, NJ |
| Gino Santini | Director | Cambridge, MA |
| Robert Yedid | Director | Princeton, NJ |
| Herman Cukier | Executive Officer | Princeton, NJ |
| Daniel Motto | Executive Officer | Princeton, NJ |
| Joseph Pergolizzi | Executive Officer | Summit, NJ |
Other filings by this issuer (3)
More